Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 5/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13543990 | 0.94 | CCR5 (0.44) | CCR5KDM1ATACR1OPRK1 | |
| SCHEMBL4680501 | 0.92 | CCR5 (0.45) | CCR5KDM1ATACR1PDE4APDE4B | |
| SCHEMBL14415552 | 0.88 | CCR5 (0.46) | CCR5TACR1PDE4APDE4BPDE4C | |
| SCHEMBL13543991 | 0.85 | CCR5 (0.43) | CCR5KDM1ATACR1OPRK1 | |
| SCHEMBL14415546 | 0.83 | CCR5 (0.51) | CCR5TACR1PDE4APDE4BPDE4C | |
| SCHEMBL4683488 | 0.81 | CCR5 (0.54) | CCR5TACR1PDE4APDE4BPDE4C | |
| SCHEMBL13544004 | 0.81 | CCR5 (0.46) | CCR5KDM1ATACR1OPRM1OPRK1 | |
| SCHEMBL27228860 | 0.79 | OPRM1 (0.46) | CCR5TACR1OPRM1USP30RORC | |
| SCHEMBL13345591 | 0.79 | CCR5 (0.46) | CCR5TACR1PDE4APDE4BPDE4C | |
| SCHEMBL3466260 | 0.79 | CCR5 (0.46) | CCR5TACR1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060058284-A1 | Pyrrolidine and azetidine compounds as ccr5 antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058284-A1 | Pyrrolidine and azetidine compounds as ccr5 antagonists | CCR5, CCL5, CXCR1 | CCR5 1/4885KDM1A 2949/4885TACR1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.